Sugi Predict

Sugi Predict / Targets / AGXT

AGXT

Alanine--glyoxylate aminotransferase · P21549 · AGXT on Sugi Atlas →

32,600 patent compounds predicted against AGXT, 15,807 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL437710 SCHEMBL437710 0.71 12/20
SCHEMBL402229 SCHEMBL402229 0.60 12/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL128937) 1.00 11/20
SCHEMBL438248 SCHEMBL438248 0.74 11/20
SCHEMBL172923 SCHEMBL172923 0.59 11/20
SCHEMBL401928 SCHEMBL401928 0.60 10/20
SCHEMBL403680 SCHEMBL403680 1.00 8/20
SCHEMBL402251 SCHEMBL402251 0.51 5/20
SCHEMBL134443 SCHEMBL134443 0.46 5/20
SCHEMBL430043 SCHEMBL430043 0.34 5/20
SCHEMBL108136 SCHEMBL108136 0.69 3/20
SCHEMBL109344 SCHEMBL109344 0.69 3/20
SCHEMBL109316 SCHEMBL109316 0.67 3/20
SCHEMBL425652 SCHEMBL425652 0.66 3/20
SCHEMBL113799 SCHEMBL113799 0.65 3/20
SCHEMBL195501 SCHEMBL195501 0.62 3/20
SCHEMBL166575 SCHEMBL166575 0.62 3/20
Biphenyl Biphenyl (SCHEMBL459042) 0.55 3/20
SCHEMBL257896 SCHEMBL257896 0.54 3/20
SCHEMBL366865 SCHEMBL366865 0.42 3/20

Clinical trials — most relevant to AGXT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India PHASE4COMPLETED
Renal Protective Effect of ACEI and ARB in Primary Hyperoxaluria PHASE3WITHDRAWN
Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old PHASE3NOT_YET_RECRUITING
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma PHASE3RECRUITING
Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients PHASE3UNKNOWN
Hydroxyproline Influence on Oxalate Metabolism PHASE1/PHASE2COMPLETED
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria PHASE2COMPLETED
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) PHASE2ENROLLING_BY_INVITATION
Study of Sodium Phenylbutyrate (ACER-001) for the Treatment of Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) PHASE2SUSPENDED
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer PHASE2WITHDRAWN
Probing the Synergistic Effect of Pre-Biotics & Iron Fortificants in Anemic Subjects PHASE1/PHASE2COMPLETED
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Effect of Tulsi (Ocimum Sanctum) on Biochemical Parameters in Young Overweight and Obese Subjects PHASE2COMPLETED
BTK Inhibitor DTRMWXHS-12 in Mantle Cell Lymphoma PHASE1COMPLETED
Tolerability of Enteral NAC in Infants PHASE1NOT_YET_RECRUITING
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects PHASE1COMPLETED
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients EARLY_PHASE1COMPLETED
Rare Kidney Stone Consortium Biobank nanRECRUITING
Markers of Liver Apoptosis After Anesthesia With Sevoflurane or Propofol nanCOMPLETED
Acute Glycine Pharmacodynamic Study nanCOMPLETED
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC nanCOMPLETED
Effects of Dual-Source Carbohydrate Intake and Liver Glycogen Repletion After Overnight Fasting. nanNOT_YET_RECRUITING
International Registry for Primary Hyperoxaluria nanWITHDRAWN
Natural History Study of FDXR Mutation-related Mitochondriopathy nanCOMPLETED
Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure nanUNKNOWN
Androgens and NAFLD Longitudinal Cohort Study nanRECRUITING
Biochemical and Genetic Markers in Liver Diseases nanUNKNOWN
Observational Study of Actigraphy in Pediatric Pulmonary Arterial Hypertension nanCOMPLETED
Effect of Blueberry Supplementation on Liver Enzymes, Muscle Injury and Respiratory Parameter in Football Athletes: A Eight-Week Training Study nanCOMPLETED
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a AGXT binder may also engage these)

ProteinNameSimilarity
Q5RDP0 — 1.000 Q5RDP0 →
Q3LSM4 — 1.000 Q3LSM4 →
Q9W3Z3 — 0.996 Q9W3Z3 →
P31030 — 0.993 P31030 →
P09139 — 0.992 P09139 →
P41689 — 0.991 P41689 →
O35423 — 0.987 O35423 →
P31029 — 0.986 P31029 →
A7SCH8 — 0.984 A7SCH8 →
Q0IG34 — 0.982 Q0IG34 →
Q54GT6 — 0.982 Q54GT6 →
Q3SGX5 — 0.982 Q3SGX5 →
J3KAR5 — 0.982 J3KAR5 →
Q64611 — 0.981 Q64611 →
Q7PRG3 — 0.981 Q7PRG3 →
Q1H003 — 0.981 Q1H003 →
P43567 — 0.980 P43567 →
B2DEV1 — 0.979 B2DEV1 →
O08374 — 0.979 O08374 →
Q5R5M8 — 0.979 Q5R5M8 →
A0A098DDI1 — 0.979 A0A098DDI1 →
Q5WKB5 — 0.979 Q5WKB5 →
B3PP20 — 0.978 B3PP20 →
Q3MBD8 — 0.978 Q3MBD8 →
Q5LD58 — 0.978 Q5LD58 →
Q8YMW8 — 0.978 Q8YMW8 →
Q474L3 — 0.978 Q474L3 →
P07896 — 0.978 P07896 →
Q4UQT6 — 0.978 Q4UQT6 →
A1BE30 — 0.978 A1BE30 →